Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Neurology

Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic...

Pfizer’s RSV Vaccine enters in the late-stage of clinical trials  As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market heats up, Pfizer is launching a crit...

Sep 07, 2021

charcot-marie-tooth-disease-market-cagr-trends-growth-size-share-forecast-therapies-therapy-therapeutics-treatment-drugs
Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies

Charcot-Marie-Tooth (CMT) disease is a rare, chronic and sensory neuropathy that causes weakness of the limbs and progresses gradually over time. It can lead to atrophy, sensory loss and complete limb dysfunction. However, rare, the condition is the most common inherited disorder that damages peripheral nerves with...

Find More
pharma-news-and-updates-for-Ascendis-MicroTransponder-BioMarin-Zimmer-Biomet-Canary-Medical
Ascendis’s SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin’s Voxzogo; Zimmer-Canary’s Smart Knee Implant; COVID-19 impact on Solid Organ Transplants

FDA's Green Flag to Ascendis's Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone Deficiency For the treatment of growth failure due to deficiency of growth hormones, the USFDA approved Ascendis Pharma's Skytrofa (lonapegsomatropin-tcgd) for children of one year and older suffering from an improper s...

Find More
recent-pharma-news-updates-for-hebabiz-pfizer-astrazeneca-bms-masimo
AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers Squibb’s Opdivo; and Masimo’s PVi

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca's 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neu...

Find More

More Views & Analysis

Von Hippel-Lindau-Market
Von Hippel-Lindau Market Space Expected to Expand at a CAGR 8.3% by 2030 Owing to Increasing Prevalence and Emerging Therapies

Rare diseases, collectively, can not be considered rare at all. According to the National Institute of Health, approximately 30 million Americans that makeup 10% of the total American population, are affected by one of the 7,000 known rare diseases. However, the challenges manifested by the Rare patient population ...

Find More

major-depressive-disorder-key-companies-emerging-therapies-market-cagr-trends-size-share-growth-forecast
Major Depressive Disorder Market Quadrant Growth Soars Owing to Expected Launch of Key Therapies

Depression is a common and serious medical condition that affects the way people behave, act and think in a negative manner. Also known as Major Depressive Disorder (MDD) or clinical depression, it leads to a persistent feeling of sadness. It affects more than 300 million people of all ages globally and is the lead...

Find More

Mounting Prevalence of Neurological Disorders and the Key Companies Bidding to Solve the Riddle

Neurological Disorders are one of the most leading causes of injuries, death, and disability. Over more than 600 Neurological Disorders are believed to affect millions of people worldwide. These disorders have a deep impact on the patients, their families, and society at large. As per the systematic analysis for th...

Find More

Latest-pharma-biotech-news-updates-for-gsk-pfizer-biontech-biovac-seres-therapeutics
Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial

Alzheimer's Association International Conference (AAIC) 2021 Opens With Thrilling Details of Pharmas and Powerful Therapeutic Discoveries  The most awaited Alzheimer’s Association International Conference 2021 (AAIC) commenced yesterday on July 26th, 2021 in Denver, Colorado, which was presented both virtua...

Find More

Transcranial Stimulation Devices Market
The New Buzz of Transcranial Stimulation Devices in the Neurological Disorders Market

Neurological disorders are one of the major causes of death and disability across the globe. As per the figures published in The Lancet journal for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016, neurological disorders accounted for DALYs, which were 276 million. The mortality and morbid...

Find More

recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus
BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M

BlueRock Therapeutics secures FDA fast track for Parkinson’s disease cell therapy BlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enroll ten patients across the US and Canada, with its prima...

Find More

Dry Age-related Macular Degeneration (Dry AMD), also called atrophic AMD, is the most common form of.....

Find More

Cell therapies now are often recommended to treat cancer in several ways, out of which CAR T-cell th.....

Find More

Lamellar Ichthyosis (LI) is an autosomal recessive congenital Ichthyosis (ARCI), which mainly affect.....

Find More

The medical device industry is a dynamic, innovative, and heterogeneous sector. The MedTech industry.....

Find More

Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....

Find More

A chronic pain condition, Complex Regional Pain Syndrome (CRPS) often affects one limb and is believ.....

Find More